Alan Lee Robin, M.D.
Dr. Robin has been dedicated to the Mid-Atlantic region for three decades. A native of Chicago, Dr. Robin received his undergraduate training at Yale University and his medical schooling at Tufts University School of Medicine, Boston Massachusetts. Dr. Robin completed his fellowship in glaucoma at the Wilmer Institute, Johns Hopkins University, Baltimore Maryland. He is a clinical professor of ophthalmology at the University of Maryland and an adjunct clinical professor for the department of veteran affairs Maryland Health Care System. He is also both an associate professor of international health at the Bloomberg School of Public Health, Johns Hopkins University, and Ophthalmology at the Wilmer Institute at Johns Hopkins University. He was on the editorial board of Graefes Archiv of Ophthalmology and former editor-in-chief of Vision and Aging; currently editor-in-chief of Glaucoma Management News and editorial board of Ophthalmologica. He has authored more than 175 papers and 25 book chapters that have appeared in peer-review journals and has been an invited lecturer on all continents.
He has delivered the Janice Kushner Memorial Lecture for the International Glaucoma Association in London. He is a founding member of the American Glaucoma Society and the Indian Glaucoma Society. He is a member of the American Ophthalmological Society, an exclusive honorary society requiring an original thesis for admission. He is also a member of the Glaucoma Research Society, an invited group of the top 75 international glaucoma specialists. In 2005, he received the American Academy of Ophthalmology’s Outstanding Humanitarian Award, and he was recently selected as one of Baltimore’s top ophthalmologists by Baltimore Magazine. In 2010 he received the Silver Fellow Award from the Association for Research in Vision and Ophthalmology. In the same. year he also received the Secretariat Award from the American Academy of Ophthalmology.
During 1978, a month with Dr. Norval Christy in Taxila, Pakistan, changed his life. He realized the magnitude of preventable blindness in less developed nations and began seeking methods of eliminating needless blindness. This led him to research that could help better preserve vision.
He has been a pioneer in laser research for glaucoma. He was instrumental in both the development of ND:YAG laser iridotomy, a portable ND:YAG laser, and creating a better definition of the utility and limitations of laser trabeculoplasty. Surgical intervention in developing nations has also been one of Dr. Robin’s interests. He has been involved with seminal research into the use of intraocular lens, mitomycin, and phacoemulsification in developing nations. He is currently one of the principal investigators of the Aravind Comprehensive Eye Survey, a population based epidemiologic study of over 17,000 individuals in Southern India.
He has worked with new surgical techniques including the AquaFlow and Viscocanalostomy. He has helped develop faster and better testing for the detection and tracking of glaucoma. Finally, Dr. Robin has been a major leader in the pharmacologic therapy for glaucoma. He has been a researcher on many of the currently used medications for glaucoma and has had pivotal roles in the development of apraclonidine, brimonidine, brinzolamide, dorzolamide, latanoprost, travoprost, and levobunolol.
He has been a consultant to many in the industry, including Alcon, Allergan, Coherent, Humphrey, IOLAB, Laser Diagnostics, Merck, Oculus, Vision Rx, Pharmacia, and Pfizer.
Our Mission is to provide the best world-class eye care to patients with glaucoma and cataracts with Visions of being a world wide leader in the research, diagnosis, management, and treatment of glaucoma and cataract. We are dedicated to the individual, caring service of each patient. We are committed to medical, professional, and patient education, and dedicated to the Values of leadership, innovation, compassion, and excellence in everything we do.
Dr. Robin has been instrumental in developing and establishing the glaucoma service at the Aravind Eye Hospital in Southern India. Aravind is the busiest eye hospital in the world. His work there has been instrumental in developing self-sustaining eye care, a increased awareness of glaucoma, and fostering research and clinical ties that have bettered patients in both India and the developing world. His work has been critical to the development of mitomycin C for glaucoma surgery, new forms of visual fields to better diagnose glaucoma, as well as a better understanding of both the prevalence of glaucoma as well as other eye diseases.
Recent Awards and Recognition
- 2010 ARVO Silver Fellow
- 2005-2010 Best Doctors in Maryland
- 2006 Membership in Glaucoma Research Society
- 2007 Top Winner, Maryland Health Care Hero
- 2007 Baltimore Magazine Top Doctor
- 2008 Hawaiian Eye Meeting Speaker of the Day
- 2005 American Academy of Ophthalmology
- 2004 American Glaucoma Society Nominee for the American Academy of Ophthalmology Humanitarian Award
- 2002 -2008 Scientific Advisory Board, Alcon Laboratories, Inc.
- 2003 Life Time Member Global Directory of Who’s Who
- 2002 Program Director, Joint Bloomberg School of Public Health and Wilmer Institute Symposium on Ethnicity and Glaucoma
- 2002 Baltimore Magazine’s Baltimore’s Top Doctors
- 2002 America’s Top Doctors
- 2002 Who’s Who in America
- 2002 Who’s Who in the 21st Century
- Utilization of Eye Care Services in Rural South India: The Aravind Comprehensive Eye Survey (ACES). (Nirmalan PK, Katz J, Robin AL, Krishnadas R, Ramakrishnan R, Thulasiraj RD, Tielsch J.) Br J Ophthalmol, 2003.
- Lens Opacities in a Rural Population of Southern India. (Nirmalan PK, Krishnadas R, Ramakrishnan R, Thusasiraj RD, Katz J, Tielsch JM, Robin AL.) Invest Ophthalmol Vis Sci, March 2003.
- Blindness and Vision Impairment in a Rural Population of Southern India: The Aravind Comprehensive Eye Survey. (R Thulasiraj RD, Nirmalan PK, Ramakrishnan R, Krishnadas, Tielsch JM, Katz J, ROBIN AL.) Ophthalmology, 2003.
- Pseudoexfoliation in a Rural Population of Southern India: The Aravind Comprehensive Eye Survey. (Krishnadas R, Nirmalan PK, Ramakrishnan R, Thulasiraj RD, Katz J, Tielsch JM, ROBIN AL.) Am J Ophthalmol, 2003.
- Glaucoma in a Rural Population of Southern India: The Aravind Comprehensive Eye Survey. (Ramakrishnan R, Nirmalan PK, Krishnadas
- Schmier JK, Covert DW, Robin A: Estimated first-year costs of prostaglandin analogues with/without adjunctive therapy for glaucoma management: A United States perspective. Current Medical Research and Opinions. 2007, in press.
- Whitson JT, Roarty JD, Vijaya L, Robin AL, Gross RD, Landry TA, Dickerson JE, Scheib SA, Scott H, Hua SY, Woodside AM, Bergamini MVW. Efficacy of Brinzolamide and Levobetaxolol in Pediatric Glaucomas: A Randomized Pediatric Trial. J Am Assoc Ped Ophthalmic Surgeons. 2008;12:239-246.
- Lee BW, Parthasarathi S, John RK, Singh K, Robin AL Predictors of and Barrriers Associated with Poor Follow-up among Glaucoma Patients in South India. Archives of Ophthalmology 2008;126:1448-1454.
- Aptel F, Masset H, Burillon C, Robin A, Denis P. The influence of quality of eye drop administration in patients wieth glaucoma or ocular hypertension. British J of Ophthalmol, 2009;93:700-701.
- Sleath BL, Krishnadas R, Cho M, Robin AL, Mehta R, Covert D, Tudor G. Patient Reported barriers to glaucoma medication access, use, and adherence in Southern India. Indian Journal of Ophthalmology, 2008;57:63-68..
- Robin AL, Clark AF, Covert DW, Krueger S, Bergamini MVW, Landry TA, Dickerson JE, Scheib SA, Realini T, Defaller JM, Cagle GD. Anterior Juxtascleral Delivery of Anecortave Acetate In Eyes With Primary Open-Angle Glaucoma: A Pilot Investigation. Am J Ophthalmol, 2009;147:45-50.
- Robin AL, Suan EP, Sjaarda RN, Callanan DG, DeFaller JD, Alcon Anecortave Acetate For IOP Research Team. Anecortave Acetate Lowers Intraocular Pressure in Eyes With Steroid-Related Ocular Hypertension. Archives of Ophthalmology. 2009;127:173-178.
- Stone JL, Robin AL,Novack GD, Covert DW, Cagle GD. An Objective Evaluation of Eye-Drop Instillation in Glaucoma Patients. Archives of Ophthalmology, 2009;127:732-736.
- Schmier JK, Covert DW, Lau EC, Robin AL. Trends in Annual Medicare Expenditures for Glaucoma Surgical Procedures from 1997 – 2006. Archives of Ophthalmology, 2009;127:900-905.
- Iskedjian M, Walker JH, Desjardins O, Robin AL, Covert DW, Bergamini MV, Einarson TR. Effect of Selected Antihypertensives, Antidiabetics, Statins, and Diuretics on Adjunctive Medical Treatment of Glaucoma: A Population Based Study. Curr Med Res. Opin. 2009; 25:1879-88.
- Schmier JK, Covert DW, Robin AL. First-Year Treatment Patterns Among New Initiators of Topical Prostaglandin Analogues. Current Medical Research and Opinion. 2009; 25: 851-858.
- Sleath B, Ballinger R, Covert D, Robin AL, Byrd JE, Tudor G. Veteran race, mail order use, glaucoma medication problems, and adherence. Am J Geriatric Pharmacotherapy. In press.
- David A. Plager, Jess T. Whitson, Peter A. Netland, Lingam Vijaya, MD, Parthasarathy Sathyan, Devindra Sood, S.R. Krishnadas, Alan L. Robin, Robert D. Gross, Sally A. Scheib, Haydn Scott, Jaime E. Dickerson, PhD, and the BETOPTIC(r) S Pediatric Study Group. Efficacy and Safety of Betaxolol Hydrochloride Ophthalmic Suspension 0.25% and Timolol Gel Forming Solution 0.25% and 0.5% in Pediatric Glaucoma: A Randomized Clinical Trial. Journal of the American Association for Pediatric Ophthalmology and Strabismus.In press.
- Sleath B, Blalock SJ, Robin AL, Hartnett MEm Covert D, Devellis B, Giangiacomo A. Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations. Eye. 2009, 1-8.
- Shmier JK, Covert DW, Robin AL: First-Year Treatment Costs Among New Initiators of Topical Prostaglandin Analogs. Clinical Ophthalmology 2009:3:637-644.
- Stewart WC, Robin AL, Sharpe ED, Hennessy A, Stewart JA. The Motivation to Perform Glaucoma Clinical Trials. Ophthalmology. In press November 2009.
Click here to download Dr. Robin's Curriculum Vitae in PDF format.